FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Luis Fayad

Research Profile

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Chemicals & Drugs

Disorders

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Luis Fayad; James Foran; Eva Giné; Georg Hess; Steven Y Hua; Peter Johnson; Jonathan L Kaufman; Michelle Kneissl; Kenneth T Luu; Fritz Offner; Ama Rohatiner; Mitchell R Smith; Erik Vandendries; Gregor Verhoef; Anjali Advani; Joseph Boni; Bertrand Coiffier; Myron Czuczman; Simon Durrant; Nam H Dang
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Jinsheng Weng; Fuliang Chu; David A Delgado; Michelle A Fanale; Luis Fayad; Larry W Kwak; Amber Luong; Hyun Jun Park; Seema Rawal; Jorge Romaguera; Rakesh Sharma; Sattva S Neelapu
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
Anas Younes; Amanda Copeland; Michelle A Fanale; Silvana de Castro Farial; Luis Fayad; Fredrick Hagemeister; Stella Kim; Larry W Kwak; John M Lambert; Rodica Morariu-Zamfir; Sattva S Neelapu; Sandrine Payrard; Jorge Romaguera; Leo I Gordon
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Luis Fayad (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Luis Fayad; James Foran; Eva Giné; Georg Hess; Steven Y Hua; Peter Johnson; Jonathan L Kaufman; Michelle Kneissl; Kenneth T Luu; Fritz Offner; Ama Rohatiner; Mitchell R Smith; Erik Vandendries; Gregor Verhoef; Anjali Advani; Joseph Boni; Bertrand Coiffier; Myron Czuczman; Simon Durrant; Nam H Dang
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(5):573-83.
2012: Jinsheng Weng; Fuliang Chu; David A Delgado; Michelle A Fanale; Luis Fayad; Larry W Kwak; Amber Luong; Hyun Jun Park; Seema Rawal; Jorge Romaguera; Rakesh Sharma; Sattva S Neelapu
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
Blood 2012;120(8):1613-23.
2012: Anas Younes; Amanda Copeland; Michelle A Fanale; Silvana de Castro Farial; Luis Fayad; Fredrick Hagemeister; Stella Kim; Larry W Kwak; John M Lambert; Rodica Morariu-Zamfir; Sattva S Neelapu; Sandrine Payrard; Jorge Romaguera; Leo I Gordon
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(22):2776-82.
2012: Michael Wang; Anas Younes; Ken H Young; Jerome Zeldis; Liang Zhang; Felipe Samaniego; Luhong Sun; Nicolaus Wagner-Bartak; Maria Badillo; Maria Bejarano; Neda Bell; Catriona Byrne; Fernando Cabanillas; Richard Champlin; Wendy Chen; Yiming Chen; Michelle A Fanale; Luis Fayad; Lei Feng; Nathan Fowler; Fredrick Hagemeister; Kimberly Hartig; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Kate J Newberry; Jorge Romaguera
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
The lancet oncology 2012;13(7):716-23.
2012: S Vadhan-Raj; M Wang; Anas Younes; X Zhou; Felipe Samaniego; N J Sarlis; J Shah; C E Bueso-Ramos; J E Cortes; Michelle A Fanale; Luis Fayad; N Fowler; Fredrick B Hagemeister; Larry W Kwak; P W McLaughlin; Robert Z Orlowski; Barbara Pro; A Rodriguez; Jorge Romaguera
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(6):1640-5.
2012: Yasuhiro Oki; Jorge Romaguera; Amanda Copeland; Michelle Fanale; Silvana de Castro Faria; Luis Fayad; Percy Ivy; L Jeffrey Medeiros; Anas Younes
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.
Leukemia & lymphoma 2012;53(5):990-2.
2012: Hagop Kantarjian; Partow Kebriaei; Monica Kwari; Anjali Advani; Richard Champlin; Jorge Cortes; Stefan Faderl; Luis Fayad; Elias Jabbour; Jeffrey Jorgensen; Farhad Ravandi; Mary Beth Rios; Michael Rytting; Robert Tarnai; Deborah Thomas; Sa A Wang; Sergernne York; Susan O'Brien
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
The lancet oncology 2012;13(4):403-11.
2011: Richard J Jones; Sattva S Neelapu; Veerabhadran Baladandayuthapani; Luis Fayad; Jorge Romaguera; Rakesh Sharma; Michael Wang; Dajun Yang; Robert Z Orlowski
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Blood 2011;118(15):4140-9.
2011: Michelle Fanale; Luis Fayad; Sandra Horowitz; Yuan Ji; Larry W Kwak; Mary Joy Liboon; Cesar Nunez; Uday Popat; Barbara Pro; Felipe Samaniego; Paolo Anderlini; Anas Younes
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
British journal of haematology 2011;154(2):284-6.
2011: Deborah A Thomas; Susan O'Brien; Stefan Faderl; John T Manning; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Jeffrey Medeiros; Jorge Cortes; Hagop Kantarjian
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
Current hematologic malignancy reports 2011;6(1):58-66.
2010: Xiao Zhou; Shyam Teegala; Auris Huen; Yuan Ji; Luis Fayad; Fredrick B Hagemeister; Gregory W Gladish; Saroj Vadhan-Raj
Incidence and risk factors of venous thromboembolic events in lymphoma.
The American journal of medicine 2010;123(10):935-41.
2010: Jorge Romaguera; Luis Fayad; Peter McLaughlin; Barbara Pro; Alma Rodriguez; Michael Wang; Pamela Weaver; Kimberly Hartig; Larry W Kwak; Tatyana Feldman; Judy Smith; Peggy Ford; Stuart Goldberg; Andrew Pecora; Andre Goy
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
British journal of haematology 2010;151(1):47-53.
2010: Jack Phan; Ali Mazloom; Tony G Zreik; Christine Wogan; Ferial Shihadeh; Maria Alma Rodriguez; Luis Fayad; Nathan Fowler; Valerie Reed; Patrecia Horace; L Jeffrey Medeiros; Bouthaina S Dabaja
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(27):4170-6.
2010: Ali Mazloom; L Jeffrey Medeiros; Peter W McLaughlin; Valerie Reed; Fernando F Cabanillas; Luis Fayad; Barbara Pro; Graciela Gonzalez; Puneeth Iyengar; Diana L Urbauer; Bouthaina S Dabaja
Marginal zone lymphomas: factors that affect the final outcome.
Cancer 2010;116(18):4291-8.
2010: Jorge Romaguera; Luis Fayad; Lei Feng; Kimberly Hartig; Pamela Weaver; Maria Alma Rodriguez; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Fernando Cabanillas; Andrew Lamb; Larry Kwak; Michael Wang
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
British journal of haematology 2010;150(2):200-8.
2009: Farhad Ravandi; Ahmed Aribi; Susan O'Brien; Stefan Faderl; Dan Jones; Alessandra Ferrajoli; Xuelin Huang; Sergernne York; Sherry Pierce; William G Wierda; Dimitrios Kontoyiannis; Srdan Verstovsek; Barbara Pro; Luis Fayad; Michael Keating; Andrew Lamb
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5425-30.
2009: Ji Eun Kim; Rajesh R Singh; Jeong Hee Cho-Vega; Elias Drakos; Yogesh Davuluri; Faisal A Khokhar; Luis Fayad; L Jeffrey Medeiros; Francisco Vega
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(10):1312-20.
2009: Bita Esmaeli; Peter McLaughlin; Barbara Pro; Felipe Samaniego; Isis Gayed; Fredrick Hagemeister; Jorge Romaguera; Fernando Cabanillas; Sattva S Neelapu; R Banay; Luis Fayad; M Wayne Saville; Larry W Kwak
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(4):709-14.
2008: Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLaughlin; Maria A Rodriguez; Larry W Kwak; Yuhong Zhou; Andrew Lamb; Jorge Romaguera
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Cancer 2008;113(10):2734-41.
2008: Issa F Khouri; Peter McLaughlin; Rima M Saliba; Chitra Hosing; Martin Korbling; Ming S Lee; L Jeffrey Medeiros; Luis Fayad; Felipe Samaniego; Amin Alousi; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Sergio Giralt; Sattva S Neelapu; Naoto T Ueno; Barry I Samuels; Fredrick Hagemeister; Larry W Kwak; Richard E Champlin
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Blood 2008;111(12):5530-6.
2008: M J Overman; L Feng; Barbara Pro; Peter McLaughlin; Mark Hess; Felipe Samaniego; Anas Younes; Jorge Romaguera; Fredrick B Hagemeister; Larry W Kwak; Fernando Cabanillas; Maria A Rodriguez; Luis Fayad
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):553-9.
2008: Yasuhiro Oki; Barbara Pro; Luis Fayad; Jorge Romaguera; Felipe Samaniego; Fredrick Hagemeister; Sattva S Neelapu; Peter McLaughlin; Andre Goy; Anas Younes
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Cancer 2008;112(4):831-6.
2008: Paolo Anderlini; Rima M Saliba; Sandra Acholonu; Sergio Giralt; Borje Andersson; Naoto T Ueno; Chitra Hosing; Issa F Khouri; Daniel Couriel; Marcos De Lima; Muzaffar H Qazilbash; Barbara Pro; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Anas Younes; Mark F Munsell; Richard E Champlin
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Haematologica 2008;93(2):257-64.
2007: Luis Fayad; Deborah Thomas; Jorge Romaguera
Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Clinical lymphoma & myeloma 2007;8 Suppl 2():S57-62.
2007: Nam H Dang; Luis Fayad; Peter McLaughlin; Jorge E Romaguara; Fredrick Hagemeister; Andre Goy; Sattva S Neelapu; Felipe Samaniego; Pamela L Walker; Michael Wang; Maria A Rodriguez; Ann T Tong; Barbara Pro
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
British journal of haematology 2007;138(4):502-5.
2007: Andres O Soriano; Michael A Thompson; Joan H Admirand; Luis Fayad; Alma M Rodriguez; Jorge Romaguera; Fredrick B Hagemeister; Barbara Pro
Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature.
American journal of hematology 2007;82(8):725-8.
2007: Elias Jabbour; Chitra Hosing; Gregory D Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry W Kwak; Luis Fayad
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
Cancer 2007;109(12):2481-9.
2007: Eucharia Iwuanyanwu; L Jeffrey Medeiros; Jorge E Romaguera; Luis Fayad
Mantle cell lymphoma with a rare involvement of the testicle.
Leukemia & lymphoma 2007;48(6):1242-3.
2007: Luis Fayad; Fredrick Hagemeister
Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed.
Leukemia & lymphoma 2007;48(4):657-8.
2007: Suizhao Wang; Shu Wang; Hoyoung Maeng; Daniel P Young; Om Prakash; Luis Fayad; Anas Younes; Felipe Samaniego
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis.
Blood 2007;109(5):2174-82.
2007: Nam H Dang; Barbara Pro; Fredrick B Hagemeister; Felipe Samaniego; Dan Jones; Barry Samuels; Maria A Rodriguez; Andre Goy; Jorge Romaguera; Peter McLaughlin; Ann T Tong; Francesco Turturro; Pamela L Walker; Luis Fayad
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
British journal of haematology 2007;136(3):439-47.
2007: Yasuhiro Oki; Peter McLaughlin; Luis Fayad; Barbara Pro; Paul F Mansfield; Gary L Clayman; L Jeffrey Medeiros; Larry W Kwak; Pramod K Srivastava; Anas Younes
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
Cancer 2007;109(1):77-83.
2006: Amar Safdar; Maria A Rodriguez; Luis Fayad; Gilhen H Rodriguez; Barbara Pro; Michael Wang; Jorge Romaguera; Andre Goy; Fredrick B Hagemeister; Peter McLaughlin; Gerald P Bodey; Larry W Kwak; Issam I Raad; Robert B Couch
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
The Journal of infectious diseases 2006;194(10):1394-7.
2006: Anas Younes; Luis Fayad; Jorge Romaguera; Barbara Pro; Andre Goy; Michael Wang
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2976-81.
2006: Apostolia-Maria Tsimberidou; Susan O'Brien; Hagop M Kantarjian; Charles Koller; Fredrick B Hagemeister; Luis Fayad; Susan Lerner; Carlos E Bueso-Ramos; Michael J Keating
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Cancer 2006;107(6):1294-302.
2006: Qi Liu; Luis Fayad; Fernando Cabanillas; Fredrick B Hagemeister; Gregory D Ayers; Mark Hess; Jorge Romaguera; Maria A Rodriguez; Apostolia-Maria Tsimberidou; Srdan Verstovsek; Anas Younes; Barbara Pro; Ming-Sheng Lee; Ana Ayala; Peter McLaughlin
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1582-9.
2006: Luis Fayad; Anas Younes
Novel treatment strategies for aggressive non-Hodgkin's lymphoma.
Expert opinion on pharmacotherapy 2006;7(6):733-48.
2006: Barbara Pro; Luis Fayad; Peter McLaughlin; Jorge Romaguera; Fredrick B Hagemeister; Maria A Rodriguez; Andre Goy; Evelyne M Loyer; Anas Younes
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Leukemia & lymphoma 2006;47(3):481-5.
2006: Anas Younes; Barbara Pro; Luis Fayad
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Blood 2006;107(4):1731-2.
2005: Jorge Romaguera; Luis Fayad; Maria A Rodriguez; Kristine Broglio; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth Katz; Harish K Gagneja; Barry Samuels; Terry L Smith; Fernando Cabanillas
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7013-23.
2005: Paolo Anderlini; Rima M Saliba; Sandra Acholonu; Grace-Julia Okoroji; Michele Donato; Sergio Giralt; Borje Andersson; Naoto T Ueno; Issa Khouri; Marcos De Lima; Chitra Hosing; Agueda Cohen; Cindy Ippoliti; Jorge Romaguera; M A Rodriguez; Barbara Pro; Luis Fayad; Andre Goy; Anas Younes; Richard E Champlin
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
Bone marrow transplantation 2005;35(10):943-51.
2005: Issa F Khouri; Rima M Saliba; Chitra Hosing; Grace-Julia Okoroji; Sandra Acholonu; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Michele L Donato; Luis Fayad; Sergio Giralt; Roy Jones; Martin Korbling; Farzaneh Maadani; John T Manning; Barbara Pro; Elizabeth J Shpall; Anas Younes; Peter McLaughlin; Richard E Champlin
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2240-7.
2005: Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge Romaguera; Fredrick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David P Schenkein; Fernando Cabanillas; Alma M Rodriguez
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):667-75.
2004: Nam H Dang; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Jorge Romaguera; Dan Jones; Barry Samuels; Felipe Samaniego; Anas Younes; Michael Wang; Andre Goy; Maria A Rodriguez; Pamela L Walker; Yolanda Arredondo; Ann T Tong; Luis Fayad
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4095-102.
2004: Maricer Escalon; Richard E Champlin; Rima M Saliba; Sandra Acholonu; Chitra Hosing; Luis Fayad; Sergio Giralt; Naoto T Ueno; Farzaneh Maadani; Barbara Pro; Michele Donato; Peter McLaughlin; Issa F Khouri
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2419-23.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Madeleine Duvic; Luis Fayad; Razelle Kurzrock
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Cancer 2004;100(2):342-9.
2003: Issa F Khouri; Ming-S Lee; Rima M Saliba; Gu Jun; Luis Fayad; Anas Younes; Barbara Pro; Sandra Acholonu; Peter McLaughlin; Ruth Katz; Richard E Champlin
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4407-12.
2003: Chul Ha; Joseph S Kong; Peter McLaughlin; Susan L Tucker; Luis Fayad; Mark A Hess; Richard B Wilder; Fernando Cabanillas; James D Cox
Stage III follicular lymphoma: long-term follow-up and patterns of failure.
International journal of radiation oncology, biology, physics 2003;57(3):748-54.
2003: Nam H Dang; Fredrick B Hagemeister; Madeleine Duvic; Jorge Romaguera; Anas Younes; Dan Jones; Barry Samuels; Luis Fayad; Barbara Pro; Felipe Samaniego; Andreas H Sarris; Andre Goy; Peter McLaughlin; Ann T Tong; Pamela L Walker; Lili Paz Tiongson; Terry L Smith; Yang O Huh; Chikao Morimoto; Maria A Rodriguez
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Oncology reports 2003;10(5):1513-8.
2003: Andre Goy; Latha Ramdas; Yvonne K Remache; Jun Gu; Luis Fayad; Kimberly J Hayes; Kevin R Coombes; Bedia A Barkoh; Ruth Katz; Richard Ford; Fernando Cabanillas; Frederic Gilles
Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations.
Laboratory investigation; a journal of technical methods and pathology 2003;83(6):913-6.
2003: Chitra Hosing; Rima M Saliba; Peter McLaughlin; Borje Andersson; Maria A Rodriguez; Luis Fayad; Fernando Cabanillas; Richard E Champlin; Issa F Khouri
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):737-44.
2003: Jorge Romaguera; L Jeffrey Medeiros; Fredrick B Hagemeister; Luis Fayad; Maria A Rodriguez; Barbara Pro; Anas Younes; Peter McLaughlin; Andre Goy; Andreas H Sarris; Nam H Dang; Felipe Samaniego; H M Brown; Harish K Gagneja; Fernando Cabanillas
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
Cancer 2003;97(3):586-91.
2003: Gregory M Chronowski; Richard B Wilder; Susan L Tucker; Chul Ha; Anas Younes; Luis Fayad; Maria A Rodriguez; Fredrick B Hagemeister; Ibrahim Barista; Fernando Cabanillas; James D Cox
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
International journal of radiation oncology, biology, physics 2003;55(1):36-43.
2002: Pamela J Schlembach; Richard B Wilder; Dan Jones; Chul Ha; Luis Fayad; Anas Younes; Fredrick Hagemeister; Mark Hess; Fernando Cabanillas; James D Cox
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
Cancer journal (Sudbury, Mass.) 2002;8(5):377-83.
2001: Samer Bibawi; D Abi-Said; Luis Fayad; Paolo Anderlini; Naoto T Ueno; RC Mehra; Issa Khouri; Sergio Giralt; James L Gajewski; Michele Donato; David F Claxton; Ira Braunschweig; Koen van Besien; Michael Andreeff; Borje S Andersson; Elihu H Estey; Richard Champlin; Donna Przepiorka
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
American journal of hematology 2001;67(4):227-33.
2001: Luis Fayad; Michael J Keating; James M Reuben; Susan O'Brien; Bang-Ning Lee; Susan Lerner; Razelle Kurzrock
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.
Blood 2001;97(1):256-63.
2000: Jose Rodriguez; Peter McLaughlin; Luis Fayad; M Santiago; Mark Hess; Maria A Rodriguez; Jorge Romaguera; Fredrick Hagemeister; Andrew Lamb; Fernando Cabanillas
Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1551-6.
1999: Jorge Cortes; Luis Fayad; Susan O'Brien; Michael Keating; Andrew Lamb
Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2491-7.
1999: E Diamandidou; MI Colome; Luis Fayad; Madeleine Duvic; Razelle Kurzrock
Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Journal of the American Academy of Dermatology 1999;40(6 Pt 1):914-24.
1999: Jose Rodriguez; Maria A Rodriguez; Luis Fayad; Peter McLaughlin; F Swan; Andreas H Sarris; Jorge Romaguera; Borje Andersson; Fernando Cabanillas; Fredrick B Hagemeister
ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.
Blood 1999;93(11):3632-6.
1999: Jose Rodriguez; Peter McLaughlin; Fredrick B Hagemeister; Luis Fayad; Maria A Rodriguez; M Santiago; Mark Hess; Jorge Romaguera; Fernando Cabanillas
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Blood 1999;93(7):2202-7.
1998: E Diamandidou; MI Colome-Grimmer; Luis Fayad; Madeleine Duvic; Razelle Kurzrock
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis.
Blood 1998;92(4):1150-9.
1998: Luis Fayad; Fernando Cabanillas; Moshe Talpaz; Peter McLaughlin; Razelle Kurzrock
High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.
Leukemia & lymphoma 1998;30(5-6):563-71.
1998: M DeLima; Maher Albitar; Susan O'Brien; Sherry Pierce; Andrew Lamb; M Andreeff; Luis Fayad; Michael Keating; Elihu Estey
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.
The American journal of medicine 1998;104(3):246-51.
1996: Luis Fayad; LE Robertson; Susan O'Brien; J T Manning; S Wright; F Hagemeister; Fernando Cabanillas; Michael J Keating
Hodgkin's disease variant of Richter's syndrome: experience at a single institution.
Leukemia & lymphoma 1996;23(3-4):333-7.